Advancing neurokinin receptor antagonists in respiratory and women’s health

February 9, 2017 Christoph Graener

Starting the year with a cash injection of GDP 23 million, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. Speaking at the 2017 Biotech Showcase, NeRRe CEO Dr. Mary Kerr tells Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how the company plans to generate Phase II data on orvepitant, a chronic respiratory candidate; and to advance NT-814 as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Mary Kerr – CEO, NeRRe Therapeutics Ltd.

Previous Article
Catabasis pursues bifunctional mutation-agnostic approach to DMD

Using its safely metabolized and rationally targeted (SMART) linker platform, Catabasis has identified an N...

Next Article
Q BioMed plans to accelerate up to four more assets

Established in June 2015, Q BioMed, the NYC-based biomedical acceleration development company, is looking t...